Palmitoyl Pentapeptide-4 (Matrixyl)
A lipopeptide that stimulates collagen and glycosaminoglycan synthesis in fibroblasts, clinically shown to reduce wrinkle depth by up to 68% over 6 months.
Community Rating
No ratings yet
Compound Profile
Palmitoyl Pentapeptide-4 (Matrixyl)
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Palmitoyl Pentapeptide-4 (Matrixyl) is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Significantly increases dermal collagen I, III, and IV synthesis - the structural proteins that maintain skin firmness
- Stimulates fibronectin and hyaluronic acid production in fibroblasts
- Clinical studies show up to 68% reduction in wrinkle depth over 6 months at 3-4% concentration
- Palmitoyl Pentapeptide-4 (Matrixyl) is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Significantly increases dermal collagen I, III, and IV synthesis - the structural proteins that maintain skin firmness
- Stimulates fibronectin and hyaluronic acid production in fibroblasts
- Clinical studies show up to 68% reduction in wrinkle depth over 6 months at 3-4% concentration
- Promotes elastin synthesis - restoring skin elasticity lost through photoaging
In Plain English
Simple summaryPalmitoyl pentapeptide-4 (Matrixyl) is probably the most commercially successful cosmetic peptide ever developed. It's a fragment of procollagen type I (the sequence Lys-Thr-Thr-Lys-Ser, modified with a palmitic acid chain for skin penetration) designed to signal to fibroblasts that collagen has been broken down -- triggering them to produce more collagen, elastin, and hyaluronic acid as a repair response. The fatty acid modification is essential: it dramatically improves penetration through the stratum corneum and into the dermis where fibroblasts live. Sederma (now part of Croda) developed it in the late 1990s and the evidence base, while partly company-sponsored, includes enough independent work to support real fibroblast stimulation at reasonable concentrations.
- Significantly increases dermal collagen I, III, and IV synthesis - the structural proteins that maintain skin firmness
- Stimulates fibronectin and hyaluronic acid production in fibroblasts
- Clinical studies show up to 68% reduction in wrinkle depth over 6 months at 3-4% concentration
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Palmitoyl Pentapeptide-4 (Matrixyl)?
Tap any underlined term for an instant definition.
Palmitoyl Pentapeptide-4, marketed as Matrixyl by Sederma, is a synthetic lipopeptide created by conjugating the fatty acid palmitic acid to the pentapeptide Lys-Thr-Thr-Lys-Ser (KTTKS). This KTTKS sequence corresponds to a procollagen type I fragment released during collagen degradation, which acts as a matrikine - a biologically active extracellular matrix fragment that signals to cells to increase collagen synthesis and replace degraded matrix.
The biological mechanism is straightforward and well-validated: the KTTKS sequence (with or without the palmitoyl fatty acid conjugation) binds to TGF-beta receptors on dermal fibroblasts, activating downstream signalling pathways (including Smad2/3) that upregulate transcription of collagen genes. The result is increased synthesis of collagen type I, III, and IV - the key structural proteins that maintain dermis firmness and volume. The palmitoyl fatty acid conjugation serves primarily to enhance skin penetration through the stratum corneum by improving lipophilicity.
Research published in the International Journal of Cosmetic Science and in multiple peer-reviewed studies has documented Matrixyl's effectiveness. The landmark controlled clinical study by Lintner and Peschard showed statistically significant reduction in wrinkle depth of up to 68% at 6 months compared to vehicle control, using a 3% concentration applied twice daily. Dermometer measurements confirmed increased skin firmness, and skin replica analysis confirmed visible wrinkle reduction. These results positioned Matrixyl as one of the most evidence-supported cosmeceutical active ingredients available.
Beyond collagen, Palmitoyl Pentapeptide-4 stimulates production of fibronectin (an extracellular matrix protein critical for cell adhesion and wound healing), hyaluronic acid (the skin's primary hydration molecule), and glycosaminoglycans that form the extracellular matrix scaffolding. This multi-target matrix rebuilding activity is what distinguishes it from simple collagen-boosting claims.
In skin research contexts, Matrixyl has become a standard tool for studying fibroblast activation, age-related ECM degradation, and photoaging models. 3D reconstructed skin models treated with Matrixyl show increased dermal thickness and improved structural organisation, providing a robust in vitro system for studying anti-aging compound mechanisms.
Matrixyl 3000 - a later formulation combining Palmitoyl Pentapeptide-4 with Palmitoyl Tetrapeptide-7 (a separate collagen-stimulating peptide) - has also been extensively studied and is considered the successor in many applications, with some evidence of enhanced efficacy from the dual-peptide combination.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Palmitoyl Pentapeptide-4 (Matrixyl). See all Skin & Anti-Aging peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Optimal topical concentration: 3-4% in finished product formulation (the research concentration used in landmark clinical studies). Lower concentrations (0.5-1%) are commonly used in commercial cosmetics but are below the clinically studied range.
Apply to clean skin 1-2 times daily. Consistent daily application is required - wrinkle reduction benefits require at least 4-8 weeks of use to become visible, with optimal results at 3-6 months. Evening application allows for sustained receptor engagement during sleep.
For research formulations, Matrixyl is typically dissolved in the aqueous phase of an emulsion or serum base. Stable at pH 4-7. Avoid high temperatures during formulation.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Topical application only. Apply to the target area (face, neck, decolletage) after cleansing and toning. Can be layered under moisturiser. No systemic delivery route is relevant for this compound's cosmeceutical applications.
For research skin models (ex vivo skin, cell culture, 3D skin equivalents): dissolve in DMSO or ethanol for stock preparation, then dilute to working concentration in culture medium or PBS.
Store formulated serums at 4-15°C and avoid UV light exposure.
What the research doesn't show
Most of the dramatic efficacy numbers come from Sederma's own studies or studies using Sederma-supplied material. Independent academic groups studying Matrixyl show real fibroblast stimulation in cell cultures and modest wrinkle improvements in small trials. 'Modest' is the honest characterization -- meaningful for a topical ingredient, but not remotely comparable to professional skin treatments.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Palmitoyl Pentapeptide-4 (Matrixyl), covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Palmitoyl Pentapeptide-4 (Matrixyl) has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: significantly increases dermal collagen i, iii, and iv synthesis - the structural proteins that maintain skin firmness.
The most commonly reported side effect in research subjects is excellent tolerability - rarely causes irritation even in sensitive skin. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
Matrixyl 3000 is a combination of palmitoyl pentapeptide-4 and palmitoyl tripeptide-1 -- often claimed to be more effective through synergistic collagen stimulation. GHK-Cu (copper peptide) also stimulates collagen and ECM remodeling but through a different mechanism (metalloproteinase regulation and wound healing signals). Among topical cosmetic peptides, Matrixyl has the strongest independent evidence base for actual collagen stimulation.
Compare Palmitoyl Pentapeptide-4 (Matrixyl) side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.